ClinicalTrials.gg
CompletedNCT05145413ARISEUpdated May 5, 2026Results posted

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules and Placebo in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 166 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
4th of 20
396 · median 178
Started
2021
with 3 others
Phase 3
14 of 20
4 open now
Registered
6th of 20
by date
Lead sponsor
7 of 20
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 14 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS) Total Score.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is aged ≥18 to \<65 years at the time of randomization
  2. Subject is capable of providing signed Form before any study assessments will be performed
  3. Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2
  4. Subject is currently being treated with stable dosing of monotherapy risperidone, paliperidone, aripiprazole, or their LAIs ziprasidone, lurasidone, or cariprazine and has been taking this treatment with the same dosing regimen for at least 8 weeks at the time of Day 1 (Visit 3)
  5. The subject has had at least 1 previous inadequate response to above antipsychotics that was dosed appropriately (within the label) for at least 6 weeks
  6. The subject has not required psychiatric hospitalization, incarceration in prison, acute crisis intervention, or other increase in the level of care due to symptom exacerbation within 8 weeks of Screening and is psychiatrically stable in the opinion of the Investigator
  7. To be eligible for randomization, subjects need to have detectable levels of background antipsychotic medication (measured at Visit 1)
  8. Positive and Negative Syndrome Scale (PANSS) total score ≥ 70 at Screening and randomization
  9. Clinical Global Impression-Severity (CGI-S) scale with a score ≥ 4 (moderate) at Screening and randomization
  10. PANSS Marder Positive symptom factor ≥ 4 on 2 (or more) items (PANSS items, delusions, hallucinations, grandiosity, suspiciousness and persecution, stereotyped thinking, somatic concern, unusual thought content or lack of judgment and insight), at Screening and randomization
  11. Subjects with ≤ 20-point decrease in PANSS Total score between Visit 1 and Visit 3
  12. Subject is willing and able to visit the clinic in an outpatient setting for the study duration, follow instructions, and comply with the protocol requirements
  13. (BMI) must be within 18 to 40 kg/m2 (inclusive of both values)
  14. Subject resides in a stable living situation in the opinion of the Investigator
  15. Subject has identified a reliable informant/ caregiver willing and able to assist with study activities as needed throughout the subject's participation in the study. The informant needs to be physically present at the Baseline visit, but can complete the remaining study visits assessments via phone (as needed and as per local regulations). In Bulgaria, the informant needs to physically present at the Baseline visit and should be physically present at all study visits where the Investigator determines that his/her input would be beneficial.
  16. Women of (WOCP), or men whose sexual partners are WOCP, must be able and willing to use at least 1 highly effective method of during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of the study drug. A female subject is considered to be a WOCP after menarche and until she is in a state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening)
  2. The subject has a history of moderate to severe substance use disorder (other than nicotine) within the past 12 months

    1. A Screening subject with mild substance use disorder within the 12 months before Screening must be discussed with the Medical Monitor before being allowed into the study
    2. Subjects who test positive for cannabis at Screening may be permitted to enroll in consultation with the Medical Monitor if the subject's pattern of use is not indicative of a moderate to severe substance use disorder
  3. Subject has a history of treatment-resistant schizophrenia defined as:

    a. Failure to minimally respond to 2 adequate courses of antipsychotic drug (APD) pharmacotherapy Note: Failure to minimally respond is defined as persistence symptoms of moderate severity in 2 or more psychotic symptom domains or persistence of severe symptoms in 1 or more psychotic symptom domains despite adequate dose and duration (6 weeks or longer) of APD treatment.

  4. History of symptom instability

    a. > 3 psychiatric hospitalizations over the last 12 months or 2 over the last 6 months

  5. Current APD is other than aripiprazole, risperidone, paliperidone, or their LAI versions, ziprasidone, lurasidone, or cariprazine
  6. Subjects who are diagnosed with schizophreniform disorder or are experiencing their first treated episode of schizophrenia
  7. Significant or severe medical conditions including pulmonary, cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject or the validity of the study results

    1. \< 60 mL/min
    2. or aspartate transaminase (AST) > 1.5 x (ULN)
    3. Total > 1.5 x ULN (Subjects with Gilbert's syndrome can be included as long as direct bilirubin is ≤ 1.5 x ULN)
  8. Subjects with (HIV), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections as indicated by medical history, serologies or LFT results
  9. History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator
  10. History of irritable bowel syndrome (with or without constipation) or any serious constipation requiring treatment within the last 6 months
  11. Risk for suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSRS as confirmed by the following:

    1. Answers "Yes" on items 4 or 5 (C-SSRS - ideation) with the most recent episode occurring within the 2 months before Screening or,
    2. Answers "Yes" to any of the 5 items (C-SSRS behavior) with an episode occurring within the 12 months before Screening
  12. abnormal finding on the physical examination, medical history, , or clinical laboratory results at Screening
  13. Urine toxicology screen is positive for phencyclidine, amphetamines, opiates, cocaine, or alcohol (clinically significant alcohol use in the opinion of the Investigator)
  14. Subject is currently taking, or plans to take while in the study, any prohibited concomitant medication.
  15. Pregnant, lactating, or less than 3 months postpartum
  16. If, in the opinion of the Investigator and/or Sponsor/Medical Monitor subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator and/or Sponsor/Medical Monitor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements
  17. Positive test for coronavirus (COVID-19) within 2 weeks or at Screening
  18. Subjects with extreme concerns relating to global pandemics, such as COVID-19, that would obscure ratings or be expected to disrupt adherence to trial procedures
  19. Unable to taper and discontinue a concomitant medication that would preclude participation in the double-blind adjunctive treatment (e.g., cannot stop anticholinergic)
  20. Subjects with prior exposure to KarXT
  21. Subjects who experienced any adverse effects due to xanomeline or trospium
  22. Subjects who received product as part of a clinical trial within 3 months of Screening
  23. Risk of violent or destructive behavior as per Investigator's judgment that would interfere with subject's participation
  24. Current involuntary hospitalization or incarcerationor on parole/probation
  25. For all male subjects only, any one of the following:

    1. History of bladder stones
    2. History of recurrent urinary tract infections
    3. Serum prostate specific antigen (PSA) >10 ng/mL
    4. An International Prostate Symptom Score (IPSS) of 5 (almost always) on either item 1, 3, 5, or 6
    5. A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9 Note: IPSS will be required only for male subjects ≥ 45 years of age. Subjects already enrolled in the study will have these assessments at their next clinic visit planned after re-consenting to determine current eligibility.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Drug: KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    KarXT 50 mg/20 mg BID KarXT 75mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

    PANSS Total Score is a clinician administered measure of schizophrenia symptom severity used widely in antipsychotic research. It includes 30 items across 3 subscales: * Positive Symptoms (7 items) assessing excesses or distortions such as hallucinations, delusions, or grandiosity * Negative Symptoms (7 items) assessing diminished function such as social withdrawal or reduced motivation and * General Psychopathology (16 items) capturing broader symptoms like anxiety, depression, guilt, or cognitive impairment Each item is scored from 1 (absent) to 7 (extreme), producing a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. Baseline is defined as the last non missing PANSS Total Score before first dose. This endpoint evaluates change from Baseline to Week 6, with negative values indicating improvement.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Change From Baseline in Personal and Social Performance Scale (PSP) at Week 6

    The Personal and Social Performance (PSP) Scale is a clinician administered assessment of personal and social functioning in individuals with schizophrenia. It evaluates functioning across four key dimensions: * Socially useful activities * Personal and social relationships * Self care and * Disturbing and aggressive behaviors The PSP is completed through a structured clinical interview and provides a total score ranging from 1 to 100, using a 6 point severity rating for each domain. Higher PSP scores indicate better personal and social functioning. The endpoint measures change from Baseline to Week 6 in PSP score, with positive values indicating improved personal and social functioning.

    Time frame: Baseline to Week 6

  2. Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6

    Change from baseline in the Clinical Global Impression-Severity (CGI-S) assesses change in overall illness severity over time as rated by the clinician. The CGI-S is a clinician-rated, single-item scale that evaluates the severity of the participant's illness at the time of assessment based on the clinician's total clinical experience with patients with the same diagnosis. Severity is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill), with higher scores indicating greater illness severity (worse outcome). Ratings are based on observed and reported symptoms, behavior, and functioning over the previous 7 days. Change from baseline is calculated as the difference between the CGI-S score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

    Time frame: Baseline to Week 6

  3. Change From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6

    Change from baseline in PANSS M-Pos Symptom Factor Score assesses change in the severity of positive symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Positive Symptom Factor score is derived from the following PANSS items: Delusions (P1), Hallucinations (P3), Grandiosity (P5), Suspiciousness/Persecution (P6), Stereotyped Thinking (N7), Somatic Concern (G1), Unusual Thought Content (G9), and Lack of Judgment and Insight (G12). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Pos factor score is calculated by summing the relevant item scores, with higher scores indicating greater positive symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Pos score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

    Time frame: Baseline to Week 6

  4. Change From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6

    Change from baseline in PANSS M-Neg Symptom Factor Score assesses change in the severity of negative symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Negative Symptom Factor score is derived from the following PANSS items: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive Social Withdrawal (N4), Lack of Spontaneity of Conversation (N6), Motor Retardation (G7), and Active Social Avoidance (G16). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Neg factor score is calculated by summing the relevant item scores, with higher scores indicating greater negative symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Neg score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

    Time frame: Baseline to Week 6

  5. Percentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

    The Positive and Negative Syndrome Scale (PANSS) is a clinician administered scale that assesses symptom severity in schizophrenia and includes 30 items across three subscales: 7 positive symptoms, 7 negative symptoms, and 16 general psychopathology symptoms. Each item is scored from 1 (absent) to 7 (extreme), generating a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. This endpoint evaluates the percentage of participants whose Week 6 PANSS Total Score decreased by at least 30% from Baseline, reflecting clinically meaningful improvement.

    Time frame: At Week 6

  6. Percentage of Participants With Preference of Medication (POM) at Week 6

    The Preference of Medication (POM) is a two item questionnaire assessing the participant's and informant's preference for the current antipsychotic compared with the most recent pre study antipsychotic. It evaluates perceived benefit or worsening relative to prior treatment. The POM uses a 5 point scale: 1 = "much better, I prefer this medication," 2 = "slightly better," 3 = "about the same," 4 = "slightly worse," 5 = "much worse, I much prefer my previous medication." Based on this scale, responses are categorized as Better (scores 1-2) or Same or Worse (scores 3-5) for both participant and informant assessments.

    Time frame: At Week 6

07

Results

Posted May 5, 2026

Participant flow

Pre-treatment Period
Participant flow — Pre-treatment Period
MilestoneKarXTPlacebo
Started197199
Completed194198
Not completed31
Withdrew: Lost to follow-up01
Withdrew: Physician decision10
Withdrew: Withdrawal by subject20
Treatment Period
Participant flow — Treatment Period
MilestoneKarXTPlacebo
Started194198
Completed161180
Not completed3318
Withdrew: Withdrawal by subject108
Withdrew: Protocol violation31
Withdrew: Lost to follow-up51
Withdrew: Physician decision42
Withdrew: Adverse event72
Withdrew: Other reasons44

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

PANSS Total Score is a clinician administered measure of schizophrenia symptom severity used widely in antipsychotic research. It includes 30 items across 3 subscales: * Positive Symptoms (7 items) assessing excesses or distortions such as hallucinations, delusions, or grandiosity * Negative Symptoms (7 items) assessing diminished function such as social withdrawal or reduced motivation and * General Psychopathology (16 items) capturing broader symptoms like anxiety, depression, guilt, or cognitive impairment Each item is scored from 1 (absent) to 7 (extreme), producing a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. Baseline is defined as the last non missing PANSS Total Score before first dose. This endpoint evaluates change from Baseline to Week 6, with negative values indicating improvement.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
Score on a ScaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6-14.3 ± 1.01-12.2 ± 0.98
Statistical analysis
  • KarXT vs Placebo · Mixed model repeated measure · p = 0.1115 · Least-squares mean difference: -2.0 · 95% CI -4.510 to 0.470MMRM includes PANSS change weeks 1-6; Fixed effects: (Treatment: Visit) interaction; Covariates: age, sex, baseline, stratification factors
SecondaryChange From Baseline in Personal and Social Performance Scale (PSP) at Week 6

The Personal and Social Performance (PSP) Scale is a clinician administered assessment of personal and social functioning in individuals with schizophrenia. It evaluates functioning across four key dimensions: * Socially useful activities * Personal and social relationships * Self care and * Disturbing and aggressive behaviors The PSP is completed through a structured clinical interview and provides a total score ranging from 1 to 100, using a 6 point severity rating for each domain. Higher PSP scores indicate better personal and social functioning. The endpoint measures change from Baseline to Week 6 in PSP score, with positive values indicating improved personal and social functioning.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Personal and Social Performance Scale (PSP) at Week 6
Score on a ScaleKarXTPlacebo
Change From Baseline in Personal and Social Performance Scale (PSP) at Week 65.3 ± 0.755.9 ± 0.73
Statistical analysis
  • KarXT vs Placebo · Mixed model repeated measure · p = 0.5219 · Least-squares mean difference: -0.6 · 95% CI -2.427 to 1.234MMRM includes PSP Total Score weeks 1-6; Fixed effects: (Treatment: Visit) interaction; Covariates: age, sex, baseline, stratification factors
SecondaryChange From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6

Change from baseline in the Clinical Global Impression-Severity (CGI-S) assesses change in overall illness severity over time as rated by the clinician. The CGI-S is a clinician-rated, single-item scale that evaluates the severity of the participant's illness at the time of assessment based on the clinician's total clinical experience with patients with the same diagnosis. Severity is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill), with higher scores indicating greater illness severity (worse outcome). Ratings are based on observed and reported symptoms, behavior, and functioning over the previous 7 days. Change from baseline is calculated as the difference between the CGI-S score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6
Score on a ScaleKarXTPlacebo
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) at Week 6-0.6 ± 0.06-0.5 ± 0.06
Statistical analysis
  • KarXT vs Placebo · Mixed model repeated measure · p = 0.14 · Least-squares mean difference: -0.1 · 95% CI -0.254 to 0.035MMRM includes CGI-S Score weeks 1-6; Fixed effects: (Treatment: Visit) interaction; Covariates: age, sex, baseline, stratification factors
SecondaryChange From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6

Change from baseline in PANSS M-Pos Symptom Factor Score assesses change in the severity of positive symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Positive Symptom Factor score is derived from the following PANSS items: Delusions (P1), Hallucinations (P3), Grandiosity (P5), Suspiciousness/Persecution (P6), Stereotyped Thinking (N7), Somatic Concern (G1), Unusual Thought Content (G9), and Lack of Judgment and Insight (G12). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Pos factor score is calculated by summing the relevant item scores, with higher scores indicating greater positive symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Pos score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6
Score on a ScaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale Marder Positive (PANSS M-Pos) Symptom Factor Score at Week 6-5.0 ± 0.36-4.2 ± 0.35
Statistical analysis
  • KarXT vs Placebo · Mixed model repeated measure · p = 0.0618 · Least-squares mean difference: -0.8 · 95% CI -1.729 to 0.042MMRM includes PANSS M-Pos Score weeks 1-6; Fixed effects: (Treatment: Visit) interaction; Covariates: age, sex, baseline, stratification factors
SecondaryChange From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6

Change from baseline in PANSS M-Neg Symptom Factor Score assesses change in the severity of negative symptoms of schizophrenia over time as rated by the clinician. The PANSS is a clinician-administered scale that evaluates symptom severity based on observed and reported symptoms. The PANSS Marder Negative Symptom Factor score is derived from the following PANSS items: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive Social Withdrawal (N4), Lack of Spontaneity of Conversation (N6), Motor Retardation (G7), and Active Social Avoidance (G16). Each item is rated on a 7-point scale (1 = absent to 7 = extreme). The PANSS M-Neg factor score is calculated by summing the relevant item scores, with higher scores indicating greater negative symptom severity (worse outcome). Change from baseline is calculated as the difference between the PANSS M-Neg score at baseline and Week 6, with negative values indicating improvement and positive values indicating worsening.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6
Score on a ScaleKarXTPlacebo
Change From Baseline in Positive and Negative Syndrome Scale Marder Negative (PANSS M-Neg) Symptom Factor Score at Week 6-3.1 ± 0.33-3.0 ± 0.32
Statistical analysis
  • KarXT vs Placebo · Mixed model repeated measure · p = 0.8162 · Least-squares mean difference: -0.1 · 95% CI -0.916 to 0.723MMRM includes PANSS M-Neg Score weeks 1-6; Fixed effects: (Treatment: Visit) interaction; Covariates: age, sex, baseline, stratification factors
SecondaryPercentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6

The Positive and Negative Syndrome Scale (PANSS) is a clinician administered scale that assesses symptom severity in schizophrenia and includes 30 items across three subscales: 7 positive symptoms, 7 negative symptoms, and 16 general psychopathology symptoms. Each item is scored from 1 (absent) to 7 (extreme), generating a PANSS Total Score ranging from 30 to 210, with higher scores indicating more severe symptoms. This endpoint evaluates the percentage of participants whose Week 6 PANSS Total Score decreased by at least 30% from Baseline, reflecting clinically meaningful improvement.

Time frame:
At Week 6
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6
Percentage of ParticipantsKarXTPlacebo
Percentage of Participants Achieving a ≥ 30% Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 637.935.0
SecondaryPercentage of Participants With Preference of Medication (POM) at Week 6

The Preference of Medication (POM) is a two item questionnaire assessing the participant's and informant's preference for the current antipsychotic compared with the most recent pre study antipsychotic. It evaluates perceived benefit or worsening relative to prior treatment. The POM uses a 5 point scale: 1 = "much better, I prefer this medication," 2 = "slightly better," 3 = "about the same," 4 = "slightly worse," 5 = "much worse, I much prefer my previous medication." Based on this scale, responses are categorized as Better (scores 1-2) or Same or Worse (scores 3-5) for both participant and informant assessments.

Time frame:
At Week 6
Reported as:
Number · Percentage of Participants
Percentage of Participants With Preference of Medication (POM) at Week 6
Percentage of ParticipantsKarXTPlacebo
Participant Preference: Better (Scores 1-2)58.550.0
Participant Preference: Same or Worse (Scores 3-5)41.550.0
Informant Preference: Better (Scores 1-2)64.352.2
Informant Preference: Same or Worse (Scores 3-5)35.747.8

Adverse events

Collected over Participants were assessed for All-Cause Mortality, SAEs and Other AEs from first dose of study medication until study completion (assessed up to approximately 175 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT0/194 (0%)2/194 (1%)60/194 (30.9%)
Placebo0/198 (0%)3/198 (1.5%)16/198 (8.1%)
Most frequent serious events
Most frequent serious events
EventKarXTPlacebo
Psychotic disorderPsychiatric disorders1/1941/198
SchizophreniaPsychiatric disorders1/1940/198
VomitingGastrointestinal disorders0/1941/198
Lumbar vertebral fractureInjury, poisoning and procedural complications0/1941/198
Most frequent other events
Most frequent other events
EventKarXTPlacebo
NauseaGastrointestinal disorders30/1946/198
VomitingGastrointestinal disorders22/1942/198
Dry mouthGastrointestinal disorders17/1943/198
SomnolenceNervous system disorders12/1947/198

Baseline characteristics

Age, Continuous
Age, Continuous(Years)KarXTPlaceboTotal
Mean41.6 ± 11.2641.8 ± 10.4141.7 ± 10.83
Sex: Female, Male
Sex: Female, Male(Participants)KarXTPlaceboTotal
Female7072142
Male127127254
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXTPlaceboTotal
Hispanic or Latino353469
Not Hispanic or Latino161163324
Unknown or Not Reported123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)KarXTPlaceboTotal
American Indian or Alaska Native123
Asian7512
Black or African American7875153
Native Hawaiian or Other Pacific Islander101
White99112211
Other10515
Not Reported101
08

Study locations

166 sites
  • IMA Clinical Research
    Phoenix, Arizona 85012, United States
  • Local Institution - 147
    Phoenix, Arizona 85012, United States
  • Pillar Clinical Research, LLC
    Little Rock, Arkansas 72204, United States
  • Woodland International Research Group, LLC
    Little Rock, Arkansas 72211, United States
  • Advanced Research Center, Inc.
    Anaheim, California 92805, United States
  • CITrials - Bellflower
    Bellflower, California 90706-7079, United States
  • Synexus Clinical Research US, Inc.
    Cerritos, California 90703, United States
  • Clinical Innovations Inc.
    Costa Mesa, California 92626, United States
  • Proscience Research Group
    Culver City, California 90230, United States
  • CenExel Collaborative Neuroscience Research
    Garden Grove, California 92845, United States
  • Omega Clinical Trials
    La Habra, California 90631, United States
  • Sunwise Clinical Research, LLC.
    Lafayette, California 94549, United States
  • Synergy Clinical Research of Escondido
    Lemon Grove, California 91945, United States
  • Encino Hospital Medical Center
    Los Angeles, California 91403, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • CNRI - Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • CenExel Clinical Innovations, Inc.
    Riverside, California 92506, United States
  • Cnri-San Diego
    San Diego, California 92123, United States
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • CenExel Collaborative Neuroscience Research
    Torrance, California 90504, United States
  • Local Institution - 186
    Coral Gables, Florida 33134, United States
  • Reliable Clinical Research LLC
    Hialeah, Florida 33012, United States
  • Galiz Research, LLC
    Hialeah, Florida 33016-1814, United States
  • Adaptive Clinical Research, Inc
    Lauderhill, Florida 33319-4985, United States
  • Behavioral Clinical Research , Inc
    Miami, Florida 33016, United States
  • Premier Clinical Research Institute, Inc.
    Miami, Florida 33122, United States
  • San Marcus Research Clinic, Inc.
    Miami Lakes, Florida 33014, United States
  • Assertive Research Center
    Miami Lakes, Florida 33016, United States
  • Envision Trials LLC
    Miami Springs, Florida 33166, United States
  • Local Institution - 124
    Orange City, Florida 32763, United States
  • Pines Care Research Center, Inc.
    Pembroke Pines, Florida 33024, United States
  • Interventional Psychiatry of Tampa Bay
    Tampa, Florida 33629, United States
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • Local Institution - 192
    Atlanta, Georgia 30331, United States
  • Local Institution - 135
    Augusta, Georgia 30912, United States
  • CenExel iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Psych Atlanta, P.C.
    Marietta, Georgia 30060, United States
  • CenExel iResearch, LLC
    Savannah, Georgia 31405, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • American Medical Research, Inc.
    Chicago, Illinois 60612-2307, United States
  • Uptown Research Institute, LLC
    Chicago, Illinois 60640, United States
  • Phoenix Medical Research, Inc.
    Prairie Village, Kansas 66208, United States
  • IMA Clinical Research
    Monroe, Louisiana 71201-2986, United States
  • CenExel Center for Behavioral Health
    Gaithersburg, Maryland 20877, United States
  • Local Institution - 158
    Boston, Massachusetts 02114, United States
  • Local Institution - 187
    Boston, Massachusetts 02118, United States
  • Local Institution - 185
    Worcester, Massachusetts 01655, United States
  • Michigan Clinical Research Institute PC
    Ann Arbor, Michigan 48105, United States
  • Cherry Health
    Grand Rapids, Michigan 49548-6927, United States
  • Western Michigan University Homer Stryker M.D. School of Medicine
    Kalamazoo, Michigan 49001, United States
  • Local Institution - 129
    St Louis, Missouri 63128, United States
  • Arch Clinical Trials LLC
    St Louis, Missouri 63141, United States
  • Omaha Insomnia and Psychiatric Services LLC
    Omaha, Nebraska 68144, United States
  • Altea Research Institute, Las Vegas
    Las Vegas, Nevada 89102, United States
  • CenExel Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Synexus Clinical Research US, Inc.
    New York, New York 10017, United States
  • Manhattan Psychiatric Center
    New York, New York 10027, United States
  • Manhattan Behavioral Medicine, PLLC
    New York, New York 10036, United States
  • Psychiatry and Alzheimer's Care of Rochester. PLLC
    Rochester, New York 14623, United States
  • Richmond Behavioral Associates ERG Clinical Research - New York PLLC
    Staten Island, New York 10314, United States
  • Clinical Trials of America - Psychiatry
    Hickory, North Carolina 28601, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Local Institution - 168
    Garfield Heights, Ohio 44125, United States
  • Insight Clinical Trials LLC
    Independence, Ohio 44131, United States
  • The Rivus Wellness & Research Institute
    Oklahoma City, Oklahoma 73112, United States
  • Prevention Science Institute
    Eugene, Oregon 97403, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78754, United States
  • InSite Clinical Research; LLC
    DeSoto, Texas 75115, United States
  • JPS Health Network
    Fort Worth, Texas 76104, United States
  • Ben Taub Hospital
    Houston, Texas 77030, United States
  • Clinical Trial Network LLC
    Houston, Texas 77074, United States
  • University Hills Clinical Research - Irving
    Irving, Texas 75062, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
  • At Health Texas
    Richmond, Texas 77407, United States
  • Perceptive Pharma Research
    Richmond, Texas 77407, United States
  • Green Mountain Research Institute
    Rutland, Vermont 05701, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • MHAT Dr. Hristo Stambolski, EOOD
    Kazanlak, Stara Zagora 6100, Bulgaria
  • Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry - Dr Ivo Natsov
    Cherven Bryag, 5980, Bulgaria
  • Medical Centre 'Asklepii', OOD
    Dupnitsa, 2600, Bulgaria
  • Medical Center Lifemed
    Kardzhali, 6600, Bulgaria
  • State Psychiatric Hospital 'Sv. Ivan Rilski', Novi Iskar
    Novi Iskar, 1282, Bulgaria
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5800, Bulgaria
  • UMHAT Sv. Georgi, EAD
    Plovdiv, 4002, Bulgaria
  • Local Institution - 321
    Plovdiv, 4004, Bulgaria
  • Local Institution - 313
    Razgrad, 7200, Bulgaria
  • MHAT Dr Ivan Seliminski AD
    Sliven, 8800, Bulgaria
  • Medical Center 'Sv.Naum'
    Sofia, 1113, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1202, Bulgaria
  • Local Institution - 320
    Sofia, 1407, Bulgaria
  • DCC 'Sv. Vrach and Sv. Sv. Kuzma and Damyan', OOD
    Sofia, 1408, Bulgaria
  • Medical Center Akademika EOOD
    Sofia, 1431, Bulgaria
  • Medical Center Hera EOOD
    Sofia, 1510, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • Medical Center VAS OOD
    Targovishte, 7700, Bulgaria
  • DCC Mladost M - Varna, OOD
    Varna, 9020, Bulgaria
  • Mental Health Center-Vratsa EOOD
    Vratsa, 3000, Bulgaria

Showing the first 100 of 166 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Mar 2025, 40 months.

Results were first posted in May 2026, 1 year 1 month after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 40 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2021
First posted
Dec 6, 2021
StartActual
Nov 12, 2021
Primary completionActual
Mar 19, 2025
CompletionActual
Mar 19, 2025
Results first posted
May 5, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05145413
Responsible party
Sponsor
First posted
Dec 6, 2021
Start date
Nov 12, 2021
Primary completion
Mar 19, 2025
Completion
Mar 19, 2025
Results posted
May 5, 2026
Last update
May 5, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion